Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bi7Tech is a Turkish biotechnology and technology transfer company founded in 2020 in collaboration with Yeditepe University. Led by CEO Selin Doğaneli Özyüksel and inspired by the research of Prof. Dr. Fikrettin Şahin, the company specializes in developing innovative healthcare products, pharmaceuticals, medical devices, and dietary supplements using patented pharma-grade boron and natural exosomal technologies. Its flagship product line, Dermobor, utilizes sodium pentaborate pentahydrate to accelerate wound healing, treat diabetic foot ulcers, prevent radiation dermatitis, and manage benign perianal diseases. Bi7Tech is actively expanding its global footprint, including securing FDA establishment registration and device listing for its Dermobor Anti-Burn Gel.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bi7Tech.